Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Sohee Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Ministry of Food and Drug Safety, National Research Foundation of Korea.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To assess the risk of amputation associated with sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) among patients with type 2 diabetes, across categories of baseline cardiovascular disease (CVD) and diuretic use (DU). Materials and Methods We conducted an active comparator, new‐user cohort study using Korea's nationwide claims data (2015‐2020). The study cohort consisted of patients with type 2 diabetes who initiated SGLT2is or dipeptidyl peptidase‐4 inhibitors (DPP4is). Cohort entry was defined by first prescription date. We then classified patients into four discrete subcohorts based on their baseline status of CVD and DU as (1) CVD+/DU+, (2) CVD+/DU‐, (3) CVD‐/DU+ and (4) CVD‐/DU‐. We performed 1:1 propensity score (PS) matching within each cohort and estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for the risk of amputation with SGLT2is versus DPP4is using Cox models.
Results
We identified 219 900 PS‐matched pairs of SGLT2is and DPP4is (CVD+/DU+, n = 11 719; CVD+/DU‐, n = 26 092; CVD‐/DU+, n = 26 894; and CVD‐/DU‐, n = 155 195), with well‐balanced baseline covariates across all cohorts. Significantly lower risks of amputation with SGLT2is versus DPP4is were found in CVD+/DU+ (HR 0.36, 95% CI 0.14‐0.90), CVD+/DU‐ (0.45, 0.21‐0.99) and CVD‐/DU‐ (0.48, 0.33‐0.70), but not in CVD‐/DU+ (0.54, 0.26‐1.12). Consistent trends in estimates were found across various sensitivity analyses.
Conclusions
Initiating SGLT2is against DPP4is did not increase the risk of amputation across patient populations of varying vulnerability. These findings based on routine practice will reassure clinicians of the safety of SGLT2is with regard to amputation risk in selected high‐risk patients with type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
- Research Department of Practice and Policy, UCL School of Pharmacy, London, UK.
- Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Republic of Korea.
- Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
- Division of Endocrinology and Metabolism, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
- Department of Internal Medicine Seoul National University College of Medicine, Seoul, South Korea.
ORCID-Profile: Young Min Cho, Ju-Young Shin
Förderung
- Ministry of Food and Drug Safety
- National Research Foundation of Korea
Zitieren
APA
Park, S., Jeong, H. E., Bea, S., Yu, O. H. Y., Cho, Y. M., You, S. C., Man, K. K. C., & Shin, J. Y. (2023). Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15221
Vancouver
Park S, Jeong HE, Bea S, Yu OHY, Cho YM, You SC, et al. Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15221
BibTeX
@article{Park2023,
author = {Park, Sohee and Jeong, Han Eol and Bea, Sungho and Yu, Oriana H Y and Cho, Young Min and You, Seng Chan and Man, Kenneth K C and Shin, Ju-Young},
title = {Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15221}
}
EUVIMED